RT Journal Article
SR Electronic
T1 A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.04.20161067
DO 10.1101/2020.08.04.20161067
A1 Marina Shevachman
A1 Abhirup Mandal
A1 Samir Mitragotri
A1 Nitin Joshi
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.04.20161067.abstract
AB The recent outbreak and rapid spread of coronavirus disease 2019 (COVID-19) is a global pandemic and a massive public health crisis. COVID-19 has also had a severe impact on the quality of life and mental health. While different health authorities such as WHO and CDC are encouraging adoption of strategies including hand washing and use of facemasks to reduce the spread of the pathogens and infections, adoption of these approaches requires substantial commitment. Current hand sanitizers based on ethanol provide immediate protection, however, the protection rendered by such sanitizers is very short-lived due to their rapid evaporation. A long-lasting sanitizing skin protectant that can effectively inactivate SARS-CoV-2 and provide persistent efficacy over several hours will provide people the freedom to carry on with their activities without constant concerns about the cleanliness of their hands. Herein, we describe a novel skin sanitizer, IonLAST™, based on an ionic liquid/deep eutectic solvent, formed by GRAS materials, choline and geranic acid (CAGE, CG-101), that provides protection for at least 4h after a single application. IonLAST™ was formulated as a gel that facilitates easy application on the skin. Tolerance of CG-101 was substantiated through a study in human volunteers. In vitro studies confirmed that IonLAST™ effectively inactivates a human coronavirus hCoV229E. A second human clinical study established that a single application of IonLAST™ imparts protection against microbes that lasts up to several hours.Competing Interest StatementCAGE Bio has a license to and ownership of patents pertaining to ionic liquids. AM, MS, and NJ are employees and shareholders of CAGE Bio. SM is a shareholder and board member/consultant to Liquideon, CAGE Bio, and i2O Therapeutics.Clinical TrialNCT04495920; NCT04498676. The studies were registered retrospectively because the studies were cosmetic phase 1 studies and it was not clear to us if registration was required and helpful.Funding StatementThis study was funded by CAGE Bio Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Gallatin Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny data associated with this study are available from the authors upon reasonable request.